EUCTR2011-002443-10-GB进行中（未招募）不适用
A Randomized, Open-Label, Single-Dose, Parallel Group Study to Evaluate the Utility of Magnetic Resonance Imaging (MRI) in Demonstrating the Nasal Decongestant Efficacy of an Active Control (Vicks® Sinex® Micromist®) Relative to a Sham Control at 8 and 12 Hours Post-Dosing
Procter & Gamble Technical Centres Ltd., UK0 个研究点目标入组 20 人开始时间: 2011年6月14日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects meeting all of the following criteria will be considered for admission to this study:
- •a)have provided written informed consent;
- •b)are generally healthy by report and review of medication/medical history;
- •c)are at least 18 years of age and not older than 65 years of age, inclusive, at screening;
- •d)report suffering from nasal congestion due to common cold or hay fever;
- •e)rate the severity of their nasal congestion as either a 2=Moderate (definite awareness of sign/symptom that is bothersome but tolerable) or 3=Severe (sign/symptom that is hard to tolerate) on the Nasal Congestion Severity Scale (Section 3.4.2.1);
- •f)if female and of child-bearing potential, have practiced abstinence or used an effective form of birth control (e.g., intrauterine device, oral contraceptives, contraceptive implants or injections, diaphragm with spermicide, cervical cap, or consort use of condom) for at least 3 months before being enrolled in the study;
- •g)have a body mass index (BMI) =18.5 but = 32 kg/m2;
- •h)be willing to refrain from exercise, alcohol, hot spicy food, hot drinks and any medication, homeopathic, home remedy, dietary supplement, herbal remedy, and saline spray listed in the exclusion criteria throughout the study;
- •i)be willing and able to comply with MRI instructions (Appendix 3);
- •j)be willing to refrain from smoking, eating and drinking during Visit 1 and starting 1 hour prior to and during Visit 2 (room temperature water will be permitted ad lib while at the site); and,
- •k)have a peak nasal inspiratory flow of < 105 L/min (Section 3.4.2.2).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 20
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects will be excluded from the study if any of the following apply:
- •a)are female and have a positive urine pregnancy test at screening or report they are pregnant, trying to become pregnant, or lactating;
- •b)have a body temperature greater than 38.1º Celsius;
- •c)have blood pressure exceeding either 138mm Hg systolic or 88mm Hg diastolic (an average of three readings after sitting for 5 minutes);
- •d)have a history of rhinitis medicamentosa or frequent nose bleeds;
- •e)have a dependence upon nasal, oral, or ocular decongestants, that, in the opinion of the Investigator would interfere with the evaluation of the study, pose a safety risk, or confound the interpretation of the study results;
- •f)have a clinically significant nasal abnormality (e.g., deviated septum, ulcer, septal perforation, or polyp) discovered during the nasal examination;
- •g)have a history of cardiovascular disease, thyroid disease, diabetes mellitus, hypertension, prostatic hypertrophy, hepatic or renal disease;
- •h)have a history of clinically significant pulmonary, autoimmune, psychiatric, metabolic, neurologic, hematologic/oncologic (except for treated basal cell carcinoma with a documented 6-month remission), metabolic, endocrine or gastrointestinal disease;
- •i)have an acute illness (other than cold and hay fever) during the two weeks preceding the study or have a condition or are taking a medication that the Investigator believes would interfere with the evaluation of the study, pose a safety risk, or confound the interpretation of the study results;
- •j)have a history of allergy or hypersensitivity or abnormal reaction to Vicks® Sinex® Micromist® or the following ingredients: oxymetazoline hydrochloride, levomenthol, sodium citrate dihydrate, tyloxapol, citric acid anhydrous, chlorhexidine gluconate solution, benzalkonium chloride solution, camphor, disodium edetate dihydrate, eucalyptol, sodium hydroxide and purified water
- •k)have a history of alcohol or drug abuse within the past 2 years;
- •l)have used intranasal or systemic corticosteroids or leukotriene antagonists/synthase inhibitors within the past 30 days;
- •m)have used inhaled, topical, or oral nedocromil or intranasal cromolyn, tricyclic antidepressant medications, or MAO inhibitors within the past 14 days;
- •n)have used intranasal or systemic decongestants or intranasal or systemic antihistamines within the past 3 days;
- •o)are taking bromocriptine, antibiotics or antiviral medications;
- •p)have consumed alcohol, nasal, throat or lung inhalants, or any products (e.g., medications, homeopathics, home remedies, dietary supplements, herbal remedies, saline sprays) for common cold or hay fever within the past 12 hours;
- •q)have exercised within the past 6 hours;
- •r)are currently enrolled in another clinical trial, or have received any other investigational drug within the past 3 months;
- •s)do not meet all the criteria in the MR Safety Screening Questionnaire (Appendix 2)
- •t)are unable to follow MRI instructions (Appendix 3);
- •u)have demonstrated an unwillingness to comply with protocol requirements (e.g., uncooperative attitude, inability to return for all scans, history of medical non-compliance) and/or poor likelihood of completing the study.
研究者
相似试验
已完成
不适用
A randomized, open-label, single-dose parallel-group trial to determine the pharmacokinetics and safety of GP2017 following a single subcutaneous injection by an autoinjector or by a pre-filled syringe in healthy male subjectsautoimmune diseasesincluding rheumatoid arthritis and psoriasis10003816NL-OMON42002Hexal AG108
进行中（未招募）
不适用
Pharmacokinetics Of Azithromycin Immediate Release And Extended Release Formulation In Kids With Acute Otitis MediaAcute otitis mediaEUCTR2014-004164-38-Outside-EU/EEAPfizer Inc38
已完成
不适用
A randomized, open-label, single dose, parallel study to evaluate the pharmacokinetics dose proportionality of GLA5PR GLARS-NF1 tablet in healthy male volunteersEndocrine, nutritional and metabolic diseaseKCT0001312GL PharmTech40
进行中（未招募）
1 期
A single center, open label,comparitive study to evaluate the Safety, Tolerability and Immunogenicity of two Formulations (with and without preservative) of 10-valent Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed) NUCOVAC® in Healthy AdultsCTRI/2013/05/003711PANACEA BIOTEC LIMITED48
已完成
2 期
A Clinical Trial to evaluate the Efficacy and Safety of Intravenous Infusion of Nanosomal Paclitaxel Lipid Suspension and Taxol in Metastatic Breast cancer patients.CTRI/2010/091/001344Intas Pharmaceuticals Ltd120